Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3)

Gynecologic Cancer Study Group of the Japan Clinical Oncology Group

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

To prospectively investigate the survival benefit of para-aortic lymphadenectomy, we launched a new study, the JCOG1412. This is a randomized Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone. Patients corresponding to possible FIGO Stage IB, II, IIIA, IIIB, and a part of IIIC1 are eligible for the first registration before surgery. Next, those patients without evidence of para-aortic lymph node metastasis and multiple pelvic lymph node metastasis during surgery will be included in the second registration and randomized to either the pelvic lymphadenectomy alone arm or the pelvic and para-aortic lymphadenectomy arm. After the initial surgery, patients with post-operative recurrence risks receive adjuvant chemotherapy. The primary endpoint is overall survival. Secondary endpoints include relapse-free survival, short-term surgical outcomes, adverse events related to adjuvant chemotherapy and recurrence patterns.

Original languageEnglish
Pages (from-to)986-990
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume47
Issue number10
DOIs
Publication statusPublished - 2017 Oct 1

Fingerprint

Medical Oncology
Endometrial Neoplasms
Lymph Node Excision
Japan
Adjuvant Chemotherapy
Recurrence
Survival
Lymph Nodes
Neoplasm Metastasis

Keywords

  • Endometrial cancer
  • Japan Clinical Oncology Group
  • Lymphadenectomy
  • Randomized controlled trial
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer : Japan Clinical Oncology Group Study 1412 (SEPAL-P3). / Gynecologic Cancer Study Group of the Japan Clinical Oncology Group.

In: Japanese Journal of Clinical Oncology, Vol. 47, No. 10, 01.10.2017, p. 986-990.

Research output: Contribution to journalArticle

@article{afe00450b9d14fcbabd4067447f08937,
title = "Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3)",
abstract = "To prospectively investigate the survival benefit of para-aortic lymphadenectomy, we launched a new study, the JCOG1412. This is a randomized Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone. Patients corresponding to possible FIGO Stage IB, II, IIIA, IIIB, and a part of IIIC1 are eligible for the first registration before surgery. Next, those patients without evidence of para-aortic lymph node metastasis and multiple pelvic lymph node metastasis during surgery will be included in the second registration and randomized to either the pelvic lymphadenectomy alone arm or the pelvic and para-aortic lymphadenectomy arm. After the initial surgery, patients with post-operative recurrence risks receive adjuvant chemotherapy. The primary endpoint is overall survival. Secondary endpoints include relapse-free survival, short-term surgical outcomes, adverse events related to adjuvant chemotherapy and recurrence patterns.",
keywords = "Endometrial cancer, Japan Clinical Oncology Group, Lymphadenectomy, Randomized controlled trial, Survival",
author = "{Gynecologic Cancer Study Group of the Japan Clinical Oncology Group} and Hidemichi Watari and Hiroshi Katayama and Taro Shibata and Kimio Ushijima and Toyomi Satoh and Takashi Onda and Daisuke Aoki and Haruhiko Fukuda and Nobuo Yaegashi and Noriaki Sakuragi",
year = "2017",
month = "10",
day = "1",
doi = "10.1093/jjco/hyx108",
language = "English",
volume = "47",
pages = "986--990",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer

T2 - Japan Clinical Oncology Group Study 1412 (SEPAL-P3)

AU - Gynecologic Cancer Study Group of the Japan Clinical Oncology Group

AU - Watari, Hidemichi

AU - Katayama, Hiroshi

AU - Shibata, Taro

AU - Ushijima, Kimio

AU - Satoh, Toyomi

AU - Onda, Takashi

AU - Aoki, Daisuke

AU - Fukuda, Haruhiko

AU - Yaegashi, Nobuo

AU - Sakuragi, Noriaki

PY - 2017/10/1

Y1 - 2017/10/1

N2 - To prospectively investigate the survival benefit of para-aortic lymphadenectomy, we launched a new study, the JCOG1412. This is a randomized Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone. Patients corresponding to possible FIGO Stage IB, II, IIIA, IIIB, and a part of IIIC1 are eligible for the first registration before surgery. Next, those patients without evidence of para-aortic lymph node metastasis and multiple pelvic lymph node metastasis during surgery will be included in the second registration and randomized to either the pelvic lymphadenectomy alone arm or the pelvic and para-aortic lymphadenectomy arm. After the initial surgery, patients with post-operative recurrence risks receive adjuvant chemotherapy. The primary endpoint is overall survival. Secondary endpoints include relapse-free survival, short-term surgical outcomes, adverse events related to adjuvant chemotherapy and recurrence patterns.

AB - To prospectively investigate the survival benefit of para-aortic lymphadenectomy, we launched a new study, the JCOG1412. This is a randomized Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone. Patients corresponding to possible FIGO Stage IB, II, IIIA, IIIB, and a part of IIIC1 are eligible for the first registration before surgery. Next, those patients without evidence of para-aortic lymph node metastasis and multiple pelvic lymph node metastasis during surgery will be included in the second registration and randomized to either the pelvic lymphadenectomy alone arm or the pelvic and para-aortic lymphadenectomy arm. After the initial surgery, patients with post-operative recurrence risks receive adjuvant chemotherapy. The primary endpoint is overall survival. Secondary endpoints include relapse-free survival, short-term surgical outcomes, adverse events related to adjuvant chemotherapy and recurrence patterns.

KW - Endometrial cancer

KW - Japan Clinical Oncology Group

KW - Lymphadenectomy

KW - Randomized controlled trial

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85030682605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030682605&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyx108

DO - 10.1093/jjco/hyx108

M3 - Article

C2 - 28981739

AN - SCOPUS:85030682605

VL - 47

SP - 986

EP - 990

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 10

ER -